<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03676114</url>
  </required_header>
  <id_info>
    <org_study_id>XuzhouMedSch3</org_study_id>
    <nct_id>NCT03676114</nct_id>
  </id_info>
  <brief_title>Effect of Perioperative Low Dose Ketamine on Postoperative Recovery in Patients Undergoing Breast Cancer Surgery</brief_title>
  <official_title>Effect of Perioperative Low Dose Ketamine on Postoperative Recovery in Patients Undergoing Breast Cancer Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Han Yuan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xuzhou Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breast cancer patients often have perioperative emotional disorders such as anxiety and
      depression, which can lead to poor quality of recovery.This study aims to determine whether
      ketamine could improve the quality of recovery in breast cancer patients. Meanwhile, it will
      show if ketamine could improve anxiety, depression, postoperative pain and fatigue.This trial
      also will bring great concerns on patients' mental health perioperatively and explore the
      measures to improve their quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2018</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>QoR40 score</measure>
    <time_frame>the first day after surgery</time_frame>
    <description>Quality of recovery will be evaluated by Quality of Recovery 40 (QoR40),which assesses five dimensions of recovery (physical comfort,emotional state, physical independence , physiological support and pain ). Each item is rated on a five-point Likert scale: none of the time, some of the time, usually, most of the time, and all the time. The total score on the QoR40 ranges from 40 (poorest quality of recovery) to 200 (best quality of recovery).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICFS scores</measure>
    <time_frame>Postoperative 3 days, 7 days and 30 days</time_frame>
    <description>Fatigue state will be evaluated by Identity Consequence Fatigue Scale (ICFS).ICFS is based on a score of 31-173, higher scores representing worse state of fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HADS scores</measure>
    <time_frame>Postoperative 2 days and 3months</time_frame>
    <description>Perioperative emotion will be evaluated by the hospital anxiety and depression scale（HADS）.The HADS is a fourteen item scale. Seven of the items relate to anxiety and seven relate to depression. The anxiety and depression subscales each range from 0 to 21, with higher scores indicating higher anxiety/depression complains. Patients were defined as having anxiety or depression or both if the score was 8 or more in the corresponding subscale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Pain</measure>
    <time_frame>3 months after surgery</time_frame>
    <description>The incidence of chronic pain at 3 months after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NRS pain scores</measure>
    <time_frame>at 4 hours, 24 hours, and 48 hours after surgery</time_frame>
    <description>Evaluate the severity using numerical rating scale（NRS）, where zero mean no pain and 10 the worst imaginable pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>Postoperative 1 day, 2 days and 3 days</time_frame>
    <description>hallucination, nightmare and delirium will be recorded</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>ketamine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>normal saline group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketamine</intervention_name>
    <description>0.5mg/kg intravenous ketamine injection before incision followed by 0.25mg/kg/hr intravenous ketamine infusion during the operation</description>
    <arm_group_label>ketamine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Same volume of normal saline will be administrated</description>
    <arm_group_label>normal saline group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. American Society of Anesthesiologists Grade I-II

          2. Patients undergoing elective breast cancer surgery under general anesthesia

        Exclusion Criteria:

          1. Unstable hypertension, history of heart disease

          2. Hepatic or renal dysfunction

          3. Patients undergoing chemotherapy before surgery

          4. Have a history of chronic pain or chronic use of analgesic

          5. Have mental illness or can't cooperate with investigators

          6. Have a history of ketamine allergy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Junli Cao</last_name>
    <phone>+86 15162160809</phone>
    <email>caojl0310@yahoo.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuan Han</last_name>
    <phone>+86 13852470693</phone>
    <email>hanyuan-trial@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Anesthesia of the Affiliated Hospital of Xuzhou Medical University</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cao Junli</last_name>
      <phone>+86 15162160809</phone>
      <email>caojl0310@yahoo.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Han Yuan</last_name>
      <phone>+86 13852470693</phone>
      <email>hanyuan_trial@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 5, 2018</study_first_submitted>
  <study_first_submitted_qc>September 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2018</study_first_posted>
  <last_update_submitted>September 19, 2018</last_update_submitted>
  <last_update_submitted_qc>September 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Xuzhou Medical University</investigator_affiliation>
    <investigator_full_name>Han Yuan</investigator_full_name>
    <investigator_title>Doctor-in-charge of Anesthetist</investigator_title>
  </responsible_party>
  <keyword>Ketamine</keyword>
  <keyword>Breast Cancer Surgery</keyword>
  <keyword>Postoperative Recovery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

